|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Docking protein-1 (DOK1) is a tumor suppressor frequently lost in malignant cells, however, it retains the ability to control activities of immune receptors in adjacent stroma cells of the tumor microenvironment.
|
31646096 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both NRIP1 and DOK1 genes are considered candidate tumor suppressor genes (TSGs).
|
28844109 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a large series of CRC patients, loss of DOK1 protein was associated with poor prognosis at early tumor stages (*p=0.001; n=1492).
|
27428427 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Interestingly, DOK1 methylation levels in HCC samples were significantly higher in the group of younger (<40 years) patients, and higher in moderately differentiated than in poorly differentiated tumors (p < 0.05).
|
27078152 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results suggest a novel mechanism of action of BRK in the promotion of tumor formation, which involves the targeting of tumor suppressor Dok1 for degradation through the ubiquitin proteasomal pathway.
|
24523872 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.
|
24809689 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The PPARg-agonist rosiglitazone prevented tumor formation in mice irrespectively of the Cav1 status and upregulated expression of the Ras-inhibitory protein docking protein-1.
|
23640045 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Control blood samples and exfoliated mouth epithelial cells from healthy individuals showed a low level of DOK1 methylation, suggesting that DOK1 hypermethylation is a tumour specific event.
|
21796618 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found a high frequency of aberrant hypermethylation of specific genes (RASSF1A, GSTP1, CHRNA3, and DOK1) in HCC tumors as compared to control cirrhotic or normal liver tissues, suggesting that aberrant hypermethylation exhibits non-random and tumor-specific patterns in HCC.
|
21146512 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our findings are suggestive for a possible tumor suppressor role of DOK1 in EOC; however its implication in enhanced EOC cell migration and proliferation restrain us to conclude that DOK1 represents a true TSG in EOC.
|
21856257 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dok1 is an adaptor tyrosine kinase substrate with tumor-suppressive activity.
|
16338067 |
2007 |